Prevalence and Patterns of Use of Psychoactive Medicines among Individuals with Autism in the Autism Society of Ohio

Journal of Autism and Developmental Disorders

Volumn 33, Issue 5, 2003, Pages 527-534

  Aman, Michael G ^a   Lam, Kristen S L ^a   Collier Crespin, Angie ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

AED; Antileptic drugs; Autism; Psychotropic drugs

Indexed keywords

AMANTADINE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZATROPINE MESILATE; BUSPIRONE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLONIDINE; DEANOL; DEXAMPHETAMINE; DIAZEPAM; DIMETHYLGLYCINE; DIPHENHYDRAMINE; FLUOXETINE; FLUVOXAMINE MALEATE; HYPERICUM PERFORATUM EXTRACT; HYPNOTIC SEDATIVE AGENT; LAMOTRIGINE; LITHIUM CARBONATE; MELATONIN; METHYLPHENIDATE; METOPROLOL; METOPROLOL TARTRATE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; OLANZAPINE; OPIATE ANTAGONIST; PROPRANOLOL; PSYCHOTROPIC AGENT; PYRIDOXINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID;

ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; AGING; AUTISM; BEHAVIOR; CHILD; DISEASE SEVERITY; DRUG TOXICITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HEALTH SURVEY; HOUSING; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; PATIENT SATISFACTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH ULCER; UNITED STATES;

ADOLESCENT; ADULT; ANTICONVULSANTS; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OHIO; PSYCHOTROPIC DRUGS; SEIZURES; SELF-HELP GROUPS; VITAMINS;

EID: 0242363152     PISSN: 01623257     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025883612879     Document Type: Review

References (24)

1. Aman, M. G. (1996). Stimulant drugs in the developmental disabilities revisited. Journal of Developmental and Physical Disabilities, 8, 347-365.
2. Aman, M. G., Arnold, L. E., & Armstrong, S. C. (1999). Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 279-289.
3. Aman, M. G., & Langworthy, K. S. (2000). Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. Journal of Autism and Developmental Disorders, 30, 451-459.
4. Aman, M. G., & Madrid, A. (1999). Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 253-263.
5. Aman, M. G., Sarphare, G., & Burrow, W. (1995). Psychoactive drugs in group homes: Prevalence and relation to demographic/psychiatric variables. American Journal on Mental Retardation, 99, 500-509.
6. Aman, M. G., Van Bourgondien, M. E., Wolford, P. C., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672-1681.
7. Bates, W. J., Smeltzer, D. J., & Arnoczky, S. M. (1986). Appropriate and inappropriate use of psychotherapeutic medications for institutionalized mentally retarded persons. American Journal of Mental Deficiency, 90, 363-370.
8. Baumeister, A. A., Sevin, J. A., & King, B. H. (1998). Neuroleptic medications. In S. Reiss & M. G. Aman (Eds.), Psychotropic medication and developmental disabilities: The International Consensus handbook (pp. 133-150). Columbus, OH: The Ohio State University Nisonger Center.
9. Findling, R. L., Maxwell, K., Scotese-Wojitila, L., Huang, J., Yamashita, T., & Wiznitzer, M. (1997). High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind, placebo-controlled study. Journal of Autism and Developmental Disorders, 27, 467-478.
10. Fraser, W. I., Ruedrich, S., Kerr, M., & Levitas, A. (1998). Beta-adrenergic blockers. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 271-289). Columbus, OH: The Ohio State University Nisonger Center.
11. Hagerman, R., Bregman, J. D., & Tirosh, E. (1998). Clonidine. In S. R. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 259-270). Columbus, OH: The Ohio State University Nisonger Center.
12. Heberlein, T. A., & Baumgarner, R. (1978). Factors affecting response rates to mailed questionnaire: A quantitative analysis of the published literature. American Sociological Review, 43, 447-462.
13. Institute of Medicine (Food and Nutrition Board). (1998). National Academy of Sciences. Washington, DC: National Academy Press.
14. Kerlinger, F. N., & Lee, H. B. (2000). Survey Research. In F. N. Kerlinger & H. B. Lee (Eds.), Foundation of behavioral research, 4th ed., (pp. 599-619). Orlando, FL: Harcourt, Inc.
15. Martin, A., Scahill, L., Klin, A., & Volkmar, F. (1999). Higher-functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 923-931.
16. Research Units on Pediatric Psychopharmacology Autism Network (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314-321.
17. Rimland, B. (1988). Controversies in the treatment of autistic children: Vitamin and drug therapy. Journal of Child Neurology, 3, S68-S72.
18. Rinck, C. (1998). Epidemiology and psychoactive medication. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 31-44). Columbus, OH: The Ohio State University Nisonger Center.
19. Rush, A. J., & Frances, A. (Eds.). (2000). Expert guideline series: Treatment of psychiatric and behavioral problems in mental retardation [Special issue]. American Journal on Mental Retardation, 105(3).
20. Schaumburg, H., Kaplan, J., Windebank, A., Vick, N., Rasmus, S., Pleasure, D., & Brown, M. J. (1983). Sensory neuropathy from pyridoxine abuse: A new megavitamin syndrome. New England Journal of Medicine, 309, 445-448.
21. Schlesselman, J. J. (1982). Case control studies. Design, conduct, analysis. New York: Oxford University Press.
22. Singh, N. N., Ellis, C. R., Mulick, J. A., & Poling, A. (1998). Vitamin, mineral, and dietary treatments for individuals with developmental disabilities. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The International Consensus handbook (pp. 311-320), Columbus, OH: The Ohio State University Nisonger Center.
23. Singh, N. N., Ellis, C. R., & Wechsler, H. A. (1998). Psychopharmacoepidemiology in mental retardation. Journal of Child and Adolescent Psychopharmacology, 7, 255-266.
24. Walter, S. D., Feinstein, A. R., Wells, C. K. (1987). Coding ordinal independent variables in multiple regression analyses. American Journal of Epidemiology, 125, 319-323.